USFDA issues EIR to Shilpa Medicare’s Bio Analytical Laboratory

25 Jun 2024 Evaluate

The U.S Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) to Shilpa Medicare’s Bio Analytical Laboratory, Unit 7, Nacharam, Hyderabad. The facility is classified as ‘No Action Indicated’ (NAI).

Bio Analytical Laboratory, Shilpa Medicare, Unit 7, Nacharam, Hyderabad, India was inspected by USFDA from February 26, 2024 to March 01, 2024. The inspection was concluded with zero 483 observations and no discussion items.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

935.80 55.90 (6.35%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.